Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Targeted therapy for non-small cell lung cancer with adjunctive probiotics and gut microbiota evolution
ChiCTR2100053837Phase 4Recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Aug 2021
- Modality
- Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Countries
- 1
01
Overview
Phase 4 trial of bacillus licheniformis in non-small cell lung cancer (NSCLC) (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Overall survival. Started Aug 2021; status: recruiting.
02
Drugs
bacillus licheniformis
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2100053837.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2100053837.